EIC, a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments, led a €20m Series B funding round in Xenothera, a Nantes-based biotech that develops “glyco-humanized” polyclonal antibodies. Additional investors include FAMM, Malakoff Humanis, Nabubuto and Anaxago. “This transaction marks the confidence of our current shareholders and XENOTHERA’s attractiveness for new investors. The entry of the European EIC Fund is also a major step for our company and strengthens its international visibility. We are obviously very happy about this significant step forward, which will also allow us to strengthen our teams and structure our production on an industrial scale, with a view to the release of commercial batches, the marketing authorization (AMM) of our XAV-19 treatment, being targeted in 2022,” Odile Duvaux, XENOTHERA President and Founder.